Q4 2025 ALX Oncology Holdings Inc Earnings Call Transcript
Key Points
- ALX Oncology Holdings Inc (ALXO) announced the permanent appointment of Dr. Barb Klencke as Chief Medical Officer, bringing extensive experience in oncology and drug development.
- The company reported significant progress in its clinical programs, particularly with Evorpacept (EVO) and ALX2004, positioning them for pivotal studies by the end of next year.
- Evorpacept demonstrated promising results in HER2-positive gastric and breast cancer trials, showing high response rates and durability, particularly in patients with high CD47 expression.
- ALX Oncology Holdings Inc (ALXO) successfully completed a $150 million financing, strengthening its balance sheet and extending its cash runway through the first half of 2028.
- The company is on track with its clinical timelines and expects to provide meaningful data readouts from its ongoing trials over the next 12 to 18 months.
- The interim data readout for the ASPEN-09-Breast trial has been pushed to mid-2027, delaying insights into the trial's progress.
- There is a need to expand the ASPEN-09-Breast trial to 120 patients to ensure robust data, indicating potential concerns about statistical power or biomarker prevalence.
- The safety data for ALX2004 has been delayed to the second half of 2026, potentially impacting investor confidence in the program's progress.
- The company faces challenges in determining the optimal CD47 cut point for patient selection, which is crucial for the success of its trials.
- There are concerns about the impact of subsequent ADC use on CD47 expression, which could affect the efficacy of Evorpacept in certain patient populations.
Greetings, and welcome to the ALX Oncology fourth-quarter 2025 financial results call and webcast. (Operator Instructions) As a reminder, this conference is being recorded.
I would now like to turn the call over to your host, Jason Lettmann, Chief Executive Officer. Thank you. You may begin.
Thank you, welcome to our Q4 and fiscal year 2025 results call. Appreciate you all spending some time with us this morning.
As usual, we will be making forward-looking statements during the call, so please refer to our FLS slide in our corporate deck. With me today, we have Harish Shantharam, our CFO as well as our CMO, Dr. Barb Klencke.
In terms of the first bit of news, we're delighted to announce today that Barb will continue leading our clinical efforts as our permanent Chief Medical Officer. Welcome, Barb. As many of you know, after joining in an interim capacity in September 2025, Barb has been absolutely instrumental in driving our development programs forward
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
